Stock data
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA) reported revenue of US$236.20M and net income of -US$5.34M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$236.20M | — | US$23.50M | -US$5.34M | — |
| 2024 | US$160.18M | — | -US$50.47M | -US$69.41M | — |
| 2023 | US$194.62M | — | -US$46.26M | -US$51.92M | — |
| 2022 | US$292.48M | — | -US$80.78M | -US$94.23M | — |
| 2021 | US$213.58M | — | -US$265.32M | -US$282.84M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$49.13M | -US$8.91M | — |
| 2026-03-31 | US$53.54M | -US$9.05M | — |
| 2025-12-31 | US$57.62M | -US$12.24M | — |
| 2025-09-30 | US$58.77M | US$0.54M | — |
| 2025-06-30 | US$62.47M | US$0.25M | — |
| 2025-03-31 | US$57.34M | US$6.11M | — |
| 2024-12-31 | US$46.50M | -US$22.80M | — |
| 2024-09-30 | US$37.43M | -US$20.04M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.